PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE

NCT06717594 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-11-28

No results posted yet for this study

Summary

A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (CAZ/AVI) alone or with CAZ/AVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and/or OXA-48).

Conditions

  • Gram Negative Infections
  • Antimicrobial Resistance (AMR)

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Maddalena Giannella, MD PhD · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717594 on ClinicalTrials.gov